Please fax all pages of completed form to your team at 888.302.1028.

To reach your team, call toll-free 844.516.3319.

You can now monitor shipments and chat online if you have questions. Go to MyAccredoPatients.com to log in or get started.

Accredo® Specialty Pharmacy Prescription & Enrollment Form

Autosomal Dominant Polycystic Kidney Disease



Four simple steps to submit your referral.

| 1 Patient Inform | ation | 110-11 | rovide copies of front and back of all medical cription insurance cards. |
|--|---------------------------|--|--|
| _ | | und prese | Emption mourance cards. |
| New patient Current patie | | | |
| | | | Middle initial |
| • | | · | ent last name |
| | • | | Last 4 digits of SSN |
| | | | Apt # |
| | | | Zip |
| | | | il address |
| | | | |
| | | | ail address |
| Alternate caregiver/contact | | | |
| | | Ema | ail address |
| OK to leave message with alte | | | |
| Patient's primary language: E | nglish Other If other, pl | ease specify | |
| | Time | Date medication n | e completed to expedite prescription fulfillment. |
| Prescriber's first name | | Last name | |
| Prescriber's title | | If NP or PA, under direct | ction of Dr |
| Office phone | Fax | NPI # | License # |
| Office contact and title | | Office conta | act email |
| Office street address | | | Suite # |
| City | | _ State | Zip |
| Prescriber's Clinical Inform | | | |
| Primary ICD-10 code (REQUIRED IS patient currently on therapy? | • | nt been treated previously for therapies tried/failed: | this condition? Yes No |
| Patient wt | Date wt obtained | | |
| NKDA Known drug allergie | es | | |
| Concurrent meds | | | |

| Patient's first name | Last name | Middle initial | Date of birth |
|-------------------------|-----------|----------------|---------------|
| Prescriber's first name | Last name | Phone | |

4 Prescribing Information

| Medication | Strength/Formulation | Directions | Quantity/Refills | |
|--|---|---|------------------|--|
| tolvaptan (generic to Jynarque®) | Prescriber: Select dose level, duration, and whether dose is part of initial titration and/or maintenance. Dispense quantity indicated up to 1-month supply per tolvaptan REMS dispensing limit. Each blister card = 7-days supply (14 tablets) Additional special instructions: | | | |
| | Standard dosing 45mg and 15mg tablet blister card 60mg and 30mg tablet blister card | Take one 45mg tablet by mouth upon waking, and one 15mg tablet 8 hours later for: 1 week 2 weeks 3 weeks 4 weeks Titration Maintenance | Refills | |
| | 90mg and 30mg tablet blister card | Take one 60mg tablet by mouth upon waking, and one 30mg tablet 8 hours later for: 1 week 2 weeks 3 weeks 4 weeks Titration Maintenance | Refills | |
| | | Take one 90mg tablet by mouth upon waking, and one 30mg tablet 8 hours later for: 1 week 2 weeks 3 weeks 4 weeks Titration Maintenance | Refills | |
| | Adjusted dosing* 15mg and 15mg tablet blister card 30mg and 15mg tablet blister card | Take one 15mg tablet by mouth upon waking, and one 15mg tablet 8 hours later for: 1 week 2 weeks 3 weeks 4 weeks Titration Maintenance | Refills | |
| | 45mg and 15mg tablet blister card | Take one 30mg tablet by mouth upon waking, and one 15mg tablet 8 hours later for: 1 week 2 weeks 3 weeks 4 weeks Titration Maintenance | Refills | |
| | *See package insert for dose adjustment for patients taking moderate CYP 3A Inhibitors. Tolvaptan is contraindicated with strong CYP 3A inhibitors. | Take one 45mg tablet by mouth upon waking, and one 15mg tablet 8 hours later for: 1 week 2 weeks 3 weeks 4 weeks Titration Maintenance | Refills | |
| Other | | | | |

If shipped to physician's office or infusion clinic, physician accepts on behalf of patient for administration in office or infusion clinic.

| Prescriber's signature required (sign below) | (Physician attests this is f | nis/her legal signature. N | O STAMPS |
|--|------------------------------|----------------------------|----------|
|--|------------------------------|----------------------------|----------|



| Date | Dispense as written | Date | Substitution allowed |
|------|---------------------|------|----------------------|

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.



The document(s) accompanying this transmission may contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents. All rights in the product names, trade amens or logos of all third-party products that appear in this form, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. © 2025 Evernorth Health Services. All rights reserved. OST-00003-110525 CRP1578603